{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:16:25Z","timestamp":1786986985297,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:00Z","timestamp":1397606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cjca.2013.08.012","type":"journal-article","created":{"date-parts":[[2014,2,8]],"date-time":"2014-02-08T11:01:27Z","timestamp":1391857287000},"page":"S42-S46","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S","title":["Combining Other Antihypertensive Drugs With \u03b2-Blockers in Hypertension: A Focus on Safety and Tolerability"],"prefix":"10.1016","volume":"30","author":[{"given":"Tiffany R.","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon W.","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2013.08.012_bib1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.08.012_bib2","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enyzme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.08.012_bib3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/01.CIR.0000112577.69066.CB","article-title":"Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes","volume":"109","author":"Mukherjee","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.08.012_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cjca.2013.01.005","article-title":"The 2013 Canadian Hypertension Education Program (CHEP) Recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"29","author":"Hackam","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2013.08.012_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004872-199816010-00016","article-title":"Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine","volume":"16","author":"Hamada","year":"1998","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.08.012_bib6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2013.08.012_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.885","article-title":"Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting","volume":"12","author":"Almenoff","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cjca.2013.08.012_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM198608143150704","article-title":"Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial","volume":"315","author":"Gibson","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.08.012_bib9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jama.1982.03320300037019","article-title":"Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2013.08.012_bib10","doi-asserted-by":"crossref","first-page":"e003640","DOI":"10.1161\/JAHA.112.003640","article-title":"Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial","volume":"1","author":"Stamler","year":"2012","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2013.08.012_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party","volume":"304","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2013.08.012_bib12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.08.012_bib13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2337\/diacare.28.3.736","article-title":"A\u00a0systematic review of drug therapy to delay or prevent type 2 diabetes","volume":"28","author":"Padwal","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2013.08.012_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archinte.158.7.741","volume":"158","author":"Savage","year":"1998","journal-title":"Arch Int Med"},{"key":"10.1016\/j.cjca.2013.08.012_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","article-title":"Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes","volume":"95","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2013.08.012_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.hjh.0000194119.42722.21","article-title":"New-onset diabetes and antihypertensive drugs","volume":"24","author":"Mancia","year":"2006","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.08.012_bib17","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1097\/HJH.0b013e328310e0d9","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes","volume":"26","author":"Ostergren","year":"2008","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.08.012_bib18","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2337\/dc07-1768","article-title":"Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Blood Pressure Lowering Arm and the relative influence of antihypertensive medication","volume":"31","author":"Gupta","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2013.08.012_bib19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2013.08.012_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1751-7176.2012.00666.x","article-title":"Blood pressure effects of combined beta-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril","volume":"14","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjca.2013.08.012_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000086521.95630.5A","article-title":"Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"42","author":"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2013.08.012_bib22","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/HJH.0b013e32833b912c","article-title":"Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?","volume":"28","author":"Chapman","year":"2010","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2013.08.012_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00315116","article-title":"Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial","volume":"39","author":"Searle","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2013.08.012_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cjca.2012.04.001","article-title":"The evolving role of \u03b2-adrenergic receptor blockers in managing hypertension","volume":"28","author":"Poirier","year":"2012","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13013676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13013676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T23:39:54Z","timestamp":1648251594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X13013676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0828282X13013676"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2013.08.012","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}